Esperion Therapeutis.Inc. buy Bank of America Co.
Summary
This prediction is currently active. The BUY prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc. has seen massive gains of 60.99%. This prediction currently runs until 15.06.24. The prediction end date can be changed by Bank_of_America_Co_ at any time. Bank_of_America_Co_ has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | 4.696% | 4.696% |
iShares Core DAX® | -1.226% | 2.804% |
iShares Nasdaq 100 | -1.845% | 2.732% |
iShares Nikkei 225® | -1.132% | -2.218% |
iShares S&P 500 | -0.980% | 1.883% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren